questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio : Questions médicales les plus fréquentes",
"headline": "Vibrio : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrionaceae",
"url": "https://questionsmedicales.fr/mesh/D014737",
"about": {
"@type": "MedicalCondition",
"name": "Vibrionaceae",
"code": {
"@type": "MedicalCode",
"code": "D014737",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio alginolyticus",
"alternateName": "Vibrio alginolyticus",
"url": "https://questionsmedicales.fr/mesh/D044149",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio alginolyticus",
"code": {
"@type": "MedicalCode",
"code": "D044149",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"url": "https://questionsmedicales.fr/mesh/D014734",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Vibrio mimicus",
"alternateName": "Vibrio mimicus",
"url": "https://questionsmedicales.fr/mesh/D044164",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio mimicus",
"code": {
"@type": "MedicalCode",
"code": "D044164",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio parahaemolyticus",
"alternateName": "Vibrio parahaemolyticus",
"url": "https://questionsmedicales.fr/mesh/D014736",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio parahaemolyticus",
"code": {
"@type": "MedicalCode",
"code": "D014736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.590"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio vulnificus",
"alternateName": "Vibrio vulnificus",
"url": "https://questionsmedicales.fr/mesh/D041261",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio vulnificus",
"code": {
"@type": "MedicalCode",
"code": "D041261",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"alternateName": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jaime Martinez-Urtaza",
"url": "https://questionsmedicales.fr/author/Jaime%20Martinez-Urtaza",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, Barcelona, Spain."
}
},
{
"@type": "Person",
"name": "Jessica L Jones",
"url": "https://questionsmedicales.fr/author/Jessica%20L%20Jones",
"affiliation": {
"@type": "Organization",
"name": "U.S. Food and Drug Administration Gulf Coast Seafood Laboratory 1 Iberville Drive UNITED STATES Dauphin Island AL 36528 2514068136."
}
},
{
"@type": "Person",
"name": "William C Walton",
"url": "https://questionsmedicales.fr/author/William%20C%20Walton",
"affiliation": {
"@type": "Organization",
"name": "2Auburn University Shellfish Laboratory, School of Fisheries, Aquaculture, and Aquatic Sciences, Auburn University, 150 Agassiz Street, Dauphin Island, AL 36528, USA."
}
},
{
"@type": "Person",
"name": "Julia C van Kessel",
"url": "https://questionsmedicales.fr/author/Julia%20C%20van%20Kessel",
"affiliation": {
"@type": "Organization",
"name": "Biology Department, Indiana University, Bloomington, Indiana, USA jcvk@indiana.edu."
}
},
{
"@type": "Person",
"name": "Blake Ushijima",
"url": "https://questionsmedicales.fr/author/Blake%20Ushijima",
"affiliation": {
"@type": "Organization",
"name": "Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent",
"datePublished": "2024-05-02",
"url": "https://questionsmedicales.fr/article/38697754",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/21505594.2024.2348251"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacokinetic analysis of ceftazidime and cefazolin in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis.",
"datePublished": "2023-12-04",
"url": "https://questionsmedicales.fr/article/38044852",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/0886022X.2023.2285873"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hijacking a small plasmid to confer high-level resistance to aztreonam-avibactam and ceftazidime-avibactam.",
"datePublished": "2023-09-27",
"url": "https://questionsmedicales.fr/article/37769749",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ijantimicag.2023.106985"
}
},
{
"@type": "ScholarlyArticle",
"name": "Carbapenem-resistant Klebsiella pneumoniae Osteoarthritis in Two Preterm Infants Treated With Ceftazidime-avibactam.",
"datePublished": "2023-09-07",
"url": "https://questionsmedicales.fr/article/37725810",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/INF.0000000000004092"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intravitreal triple therapy with vancomycin, ceftazidime, and moxifloxacin for bacterial endophthalmitis: A Twelve-year experience.",
"datePublished": "2023-05-25",
"url": "https://questionsmedicales.fr/article/37227476",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00417-023-06112-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio",
"description": "Comment diagnostiquer une infection à Vibrio ?\nQuels tests sont utilisés pour identifier Vibrio ?\nLes tests sérologiques sont-ils utiles ?\nPeut-on diagnostiquer Vibrio par PCR ?\nQuels symptômes orientent vers un diagnostic de Vibrio ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio",
"description": "Quels sont les symptômes d'une infection à Vibrio ?\nLa diarrhée est-elle toujours présente ?\nLes infections à Vibrio causent-elles de la fièvre ?\nY a-t-il des symptômes graves associés ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio",
"description": "Comment prévenir les infections à Vibrio ?\nLe lavage des mains est-il important ?\nLes vaccinations existent-elles contre Vibrio ?\nFaut-il éviter certains aliments ?\nLes voyages augmentent-ils le risque d'infection ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio",
"description": "Quel est le traitement principal pour Vibrio ?\nQuels antibiotiques sont efficaces contre Vibrio ?\nLa réhydratation est-elle toujours nécessaire ?\nLes traitements sont-ils différents selon le type de Vibrio ?\nLes probiotiques aident-ils dans le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio",
"description": "Quelles complications peuvent survenir avec Vibrio ?\nLa déshydratation est-elle une complication fréquente ?\nLes infections à Vibrio peuvent-elles être mortelles ?\nY a-t-il des risques pour les personnes immunodéprimées ?\nLes infections cutanées sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio",
"description": "Quels sont les principaux facteurs de risque pour Vibrio ?\nLes personnes âgées sont-elles plus à risque ?\nLe diabète augmente-t-il le risque d'infection ?\nLes personnes vivant près de l'eau sont-elles plus exposées ?\nLes voyages dans des zones endémiques sont-ils risqués ?",
"url": "https://questionsmedicales.fr/mesh/D014733?mesh_terms=Ceftazidime&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection à Vibrio ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures bactériennes à partir d'échantillons de selles."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier Vibrio ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture et des tests biochimiques spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les tests sérologiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques ne sont généralement pas utilisés pour Vibrio."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer Vibrio par PCR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la PCR peut être utilisée pour détecter l'ADN de Vibrio dans les échantillons."
}
},
{
"@type": "Question",
"name": "Quels symptômes orientent vers un diagnostic de Vibrio ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes gastro-intestinaux comme la diarrhée aiguë peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection à Vibrio ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée, vomissements, douleurs abdominales et fièvre."
}
},
{
"@type": "Question",
"name": "La diarrhée est-elle toujours présente ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la diarrhée est fréquente mais pas systématique dans les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio causent-elles de la fièvre ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre peut accompagner les infections à Vibrio, mais ce n'est pas toujours le cas."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes graves associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes graves peuvent inclure déshydratation et choc septique dans les cas sévères."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître rapidement, souvent dans les 24 heures suivant l'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections à Vibrio ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez de consommer des fruits de mer crus ou mal cuits et lavez-vous les mains."
}
},
{
"@type": "Question",
"name": "Le lavage des mains est-il important ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lavage des mains réduit le risque d'infection par Vibrio et d'autres pathogènes."
}
},
{
"@type": "Question",
"name": "Les vaccinations existent-elles contre Vibrio ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin efficace contre les infections à Vibrio."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, évitez les fruits de mer crus, surtout en période de chaleur ou d'épidémies."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infection ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est endémique augmente le risque d'infection."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour Vibrio ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation, souvent accompagnée d'antibiotiques si nécessaire."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont efficaces contre Vibrio ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antibiotiques comme la doxycycline et l'azithromycine sont souvent utilisés."
}
},
{
"@type": "Question",
"name": "La réhydratation est-elle toujours nécessaire ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhydratation est cruciale, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le type de Vibrio ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le traitement peut varier selon le type de Vibrio et la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "Les probiotiques aident-ils dans le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les probiotiques peuvent aider à restaurer la flore intestinale, mais ne remplacent pas le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Vibrio ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la déshydratation sévère, le choc septique et l'insuffisance rénale."
}
},
{
"@type": "Question",
"name": "La déshydratation est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la déshydratation est une complication courante, surtout en cas de diarrhée sévère."
}
},
{
"@type": "Question",
"name": "Les infections à Vibrio peuvent-elles être mortelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans les cas graves, les infections à Vibrio peuvent être mortelles sans traitement rapide."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques pour les personnes immunodéprimées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées sont à risque accru de complications graves."
}
},
{
"@type": "Question",
"name": "Les infections cutanées sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Vibrio peut causer des infections cutanées, surtout après des blessures en milieu aquatique."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour Vibrio ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent la consommation de fruits de mer crus et l'immunodépression."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de complications graves liées à Vibrio."
}
},
{
"@type": "Question",
"name": "Le diabète augmente-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut augmenter le risque d'infections graves à Vibrio."
}
},
{
"@type": "Question",
"name": "Les personnes vivant près de l'eau sont-elles plus exposées ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être plus exposées aux infections à Vibrio, surtout en été."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones endémiques sont-ils risqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, voyager dans des zones où Vibrio est courant augmente le risque d'infection."
}
}
]
}
]
}
This study aimed at revealing the underlying mechanisms of the loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing hypervirulent...
Here we longitudinally recovered 3 non-carbapenemase-producing K1-ST23 hvKp strains at a one-month interval (KP29105, KP29499 and KP30086) from an elderly male. Antimicrobial susceptibility testing, w...
Among the 3 hvKp strains, KP29105 was resistant to the third- and fourth-generation cephalosporins, KP29499 acquired resistance to both ceftazidime-avibactam and carbapenems, while KP30086 restored it...
In summary, we reported the rare ceftazidime-avibactam resistance in a non-carbapenemase-producing hvKp strain. Resistance plasmid carrying...
Peritoneal dialysis-related peritonitis (PDRP) presents a significant challenge for nephrologists. Continuous intraperitoneal cefazolin and ceftazidime are recommended for the treatment of peritonitis...
From February 2017 to December 2019, 42 PDRP patients (17 males, 25 females; mean age: 50.7 ± 12.1 years; mean body weight: 60.9 ± 11.8 kg) were recruited for the study, all participants were anuric. ...
In the traditional group, the highest and lowest serum concentrations of ceftazidime were 35.9 and 21.7 µg/mL, respectively. The highest concentration of cefazolin was 54.6 µg/mL on day 5 and the lowe...
Intraperitoneal administration of cefazolin and ceftazidime at a dose of 1 g twice daily for 5 days and then once daily for the rest of the treatment period ensured adequate therapeutic levels of anti...
Acquired β-lactamase-encoding genes are typically carried by large plasmids in Gram-negative bacteria, which also commonly carry multi-copy small plasmids. This study found that mobile genetic element...
The emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a major threat to global public health. CRKP infections are challenging to treat owing to the limited number of antibiotic spec...
We describe 2 preterm infants with CRKP osteoarthritis treated with CAZ-AVI in a tertiary children's hospital in China. Clinical characteristics, laboratory and microbiologic data, treatment and follo...
The 2 cases were both premature infants who contracted sepsis and CRKP osteoarthritis. Meropenem and polymyxin B were initially chosen for the first infant. CAZ-AVI was then used due to persistent inf...
This is the first report on the use of CAZ-AVI to treat CRKP osteoarthritis in premature infants. Successful treatment depends on prompt recognition of the pathogen and treatment with a combination of...
Increasing rates of antibiotic resistance in endophthalmitis have been reported. This study examines outcomes of triple therapy with intravitreal vancomycin, ceftazidime, and moxifloxacin for endophth...
Retrospective, consecutive series of all patients treated with abovementioned intravitreal antibiotics from January 2009 to June 2021. Percentages of eyes attaining greater than or equal to 20/200 and...
112 eyes met inclusion criteria. 63 of 112 eyes (56%) achieved a visual acuity of 20/200 during follow-up, with 39 (35%) returning to at least 20/50. In subgroup analysis, 23 of 24 (96%) eyes with pos...
Intravitreal moxifloxacin (160 µg/0.1 mL) was well tolerated as an adjunct to vancomycin and ceftazidime for bacterial endophthalmitis. Use of this novel combination offers several theoretical advanta...
To describe the clinical and microbiological features of a case of community-acquired infection by KPC-producing K. pneumoniae (KPCKP) resistant to ceftazidime/avibactam (CAZ-AVI)....
Identification of microorganisms was performed with MALDI Biotyper CA System (BrukerDaltonics, Madrid, Spain). Antimicrobial susceptibility testing was performed using Sensitre EURGNCOL panels (Thermo...
Blood culture and rectal swab KPCKP isolates were resistant to carbapenems and to CAZ-AVI. The blood culture isolate showed susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX), but the rectal sw...
Resistance to ceftazidime-avibactam is an emerging nosocomial problem. This case shows that CAZ-AVI-resistant KPCKP strains may disseminate into the community and cause serious infections....
Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime-avibactam (CAZ-AVI) is a newer combination of β-lactam/β-lactamase inhibitor, with act...
We searched PubMed, Embase and Google Scholar for clinical application in CAZ-AVI for MDR-GNB infections. Reference lists were reviewed and synthesized for narrative review....
MDRGNB infections are associated with higher mortality significantly comparing to drug-susceptible bacterial infections. Fortunately, CAZ-AVI shows significant benefits for infections due to KPC or OX...
CAZ-AVI appears to be a valuable therapeutic option in MDR-GNB infections. Using CAZ-AVI appropriately to improve efficacy and decrease the emergence of resistance is important....
The present report firstly described a critically ill patient receiving a dosing regimen of ceftazidime-avibactam (CAZ-AVI) (1.875g q24h) to eliminate multidrug-resistant Klebsiella pneumoniae and a s...
In the present work, sandwich-like polycaprolactone/gelatin/polycaprolactone electrospun multilayered mats were implemented to control the release of ceftazidime (CTZ). The outer layers were made from...
Five Enterobacter cloacae isolates were subjected to 10-day serial passage in broth microdilution with cefepime, meropenem, or ceftazidime-avibactam to evaluate increases in minimum inhibitory concent...